NovoCure Ltd stock (JE00B6T5S470): Up 40% YTD on oncology innovation

NovoCure Ltd shares have surged 40% year-to-date to $18.10, fueled by Tumor Treating Fields therapy progress in solid tumor treatment, with analysts eyeing $27.29 target.

NovoCure Ltd stock has risen 40.0% year-to-date, moving from $12.93 at the start of 2026 to $18.10, according to MarketBeat as of May 2026. The oncology innovator's shares traded at $18.24 midday on Nasdaq amid positive sentiment for its Tumor Treating Fields (TTFields) technology.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: NovoCure Limited
• Sector/industry: Medical Devices / Oncology
• Headquarters/country: Jersey
• Core markets: Global, with US focus
• Key revenue drivers: TTFields therapy sales
• Home exchange/listing venue: Nasdaq (NVCR)
• Trading currency: USD

NovoCure Ltd: core business model

NovoCure Ltd develops and markets Tumor Treating Fields (TTFields), a non-invasive anti-mitotic therapy for solid tumors using low-intensity alternating electric fields delivered via a wearable device. The FDA-approved Optune system targets glioblastoma, with ongoing trials for lung, ovarian and pancreatic cancers, per company filings on investor site as of 2026. This disrupts cancer cell division without systemic toxicity.

Revenue stems from device rentals and disposables in the US and Europe, where glioblastoma represents the primary market. NovoCure reported a market cap of $2.11 billion with 262,760 shares traded recently versus 1.81 million average volume, according to MarketBeat May 2026 data.

Main revenue and product drivers for NovoCure Ltd

TTFields therapy drives nearly all revenue, with Optune for glioblastoma generating the bulk in the US market, which accounts for significant patient adoption. Expansion into mesothelioma via NovoTTF-100A (now approved) adds growth potential. The 52-week range of $9.82-$20.06 reflects volatility tied to clinical milestones, per exchange data.

Trailing EPS stands at -$1.53 with no dividend, focusing resources on R&D for broader indications. Analysts track patient compliance and reimbursement rates as key metrics for US revenue scalability.

Industry trends and competitive position

The medical device sector sees oncology devices like TTFields gaining traction amid demand for targeted therapies, with NovoCure positioned uniquely against radiation/chemo alternatives. US investors note its Nasdaq listing and exposure to the $200B+ oncology market, per sector reports.

Why NovoCure Ltd matters for US investors

Listed on Nasdaq as NVCR, NovoCure offers US retail investors direct access to innovative oncology tech with strong FDA backing. Its US patient base and clinical trials underscore relevance to American healthcare spending trends.

Conclusion

NovoCure Ltd has delivered a 40% YTD stock gain amid TTFields commercialization, with a $2.11B market cap and analyst targets at $27.29. Trading at $18.10 on Nasdaq, it remains focused on oncology innovation. US investors track clinical progress and revenue ramps in this volatile biotech space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.